A smart, practical, deep learning-based clinical decision support tool for patients in the prostate-specific antigen gray zone: model development and validation

Author:

Song Sang Hun12ORCID,Kim Hwanik3,Kim Jung Kwon12,Lee Hakmin12,Oh Jong Jin12,Lee Sang-Chul12,Jeong Seong Jin12,Hong Sung Kyu12,Lee Junghoon4,Yoo Sangjun4,Choo Min-Soo4,Cho Min Chul4,Son Hwancheol4,Jeong Hyeon4,Suh Jungyo56,Byun Seok-Soo178

Affiliation:

1. Department of Urology, Seoul National University Bundang Hospital , Seongnam, South Korea

2. Department of Urology, Seoul National University College of Medicine , Seoul, South Korea

3. Department of Urology, Hallym University Sacred Heart Hospital , Anyang, South Korea

4. Department of Urology, Seoul Metropolitan Government–Seoul National University Boramae Medical Center , Seoul, South Korea

5. Department of Urology, Asan Medical Center , Seoul, South Korea

6. Bioinformatics Center of Curigin Ltd. , Seoul, South Korea

7. Department of Medical Device Development, Seoul National University College of Medicine , Seoul, South Korea

8. Procagen , Seongnam, South Korea

Abstract

Abstract Objective Despite efforts to improve screening and early detection of prostate cancer (PC), no available biomarker has shown acceptable performance in patients with prostate-specific antigen (PSA) gray zones. We aimed to develop a deep learning-based prediction model with minimized parameters and missing value handling algorithms for PC and clinically significant PC (CSPC). Materials and Methods We retrospectively analyzed data from 18 824 prostate biopsies collected between March 2003 and December 2020 from 2 databases, resulting in 12 739 cases in the PSA gray zone of 2.0–10.0 ng/mL. Dense neural network (DNN) and extreme gradient boosting (XGBoost) models for PC and CSPC were developed with 5-fold cross-validation. The area under the curve of the receiver operating characteristic (AUROC) was compared with that of serum PSA, PSA density, free PSA (fPSA) portion, and prostate health index (PHI). Results The AUROC values in the DNN model with the imputation of missing values were 0.739 and 0.708 (PC) and 0.769 and 0.742 (CSPC) in internal and external validation, whereas those of the non-imputed dataset were 0.740 and 0.771 (PC) and 0.807 and 0.771 (CSPC), respectively. The performance of the DNN model was like that of the XGBoost model, but better than all tested clinical biomarkers for both PC and CSPC. The developed DNN model outperformed PHI, serum PSA, and percent-fPSA with or without missing value imputation. Discussion DNN models for missing value imputation can be used to predict PC and CSPC. Further validation in real-life scenarios are need to recommend for actual implementation, but the results from our study support the increasing role of deep learning analytics in the clinical setting. Conclusions A deep learning model for PC and CSPC in PSA gray zones using minimal, routinely used clinical parameter variables and data imputation of missing values was successfully developed and validated.

Funder

Technology development Program

Ministry of SMEs and Startups

Publisher

Oxford University Press (OUP)

Subject

Health Informatics

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3